Global CRISPR Gene Editing Therapies Market 2026 - 2035
Report Overview
The CRISPR gene editing therapies market is projected to grow from USD 4.71 billion in 2026 to USD 18.96 billion by 2035 at a 12.9% CAGR (2025 base of USD 3.84 billion). Growth follows the first commercial CRISPR therapy approvals and pipeline expansion.
.webp)
Market Highlights
- North America held nearly 48% of the market in 2025.
- Asia Pacific is expected to grow fastest, at a 17.3% CAGR, driven by 80+ registered CRISPR trials in China in 2025.
- Ex vivo therapies held about 67% of the market in 2025.
- In vivo therapies are the fastest-growing type, with a projected 19.8% CAGR from 2026 to 2035.
- CRISPR-Cas9 held about 54% of the technology segment in 2025.
- Genetic disorders held about 44% of the application market in 2025.
Significant Growth Factors
Commercial Launch of First CRISPR Therapies
The FDA approved Casgevy (Vertex and CRISPR Therapeutics) and Lyfgenia in December 2023, and the EMA approved Casgevy in February 2024 - a major commercial validation of CRISPR as a therapeutic platform. Related investment reportedly reached about USD 4.8 billion in 2024, and the early-2025 pipeline included around 190 active trials.
Expansion Beyond Hemoglobinopathies
Forecast growth is linked to new indications. Oncology, especially CRISPR-enhanced CAR-T and allogeneic off-the-shelf cell therapies, is the largest commercial opportunity. Cardiovascular programs targeting PCSK9 in the liver are also highlighted.
Major Technical Advances
Base editing (Beam Therapeutics) and prime editing (Prime Medicine) are improvements over Cas9 in precision and safety. Lipid nanoparticle delivery enables liver and extrahepatic in vivo editing, with Intellia's NTLA-2001 as an early example of durable in vivo editing.
Category Wise Insights
By Type
Ex vivo therapies lead due to their maturity and regulatory precedent - cells are edited outside the body, characterized, and tested before infusion.
By Technology
CRISPR-Cas9 leads, supported by clinical experience and approved products; high-fidelity Cas9 variants are increasingly used.
By Application
Genetic disorders lead, reflecting the need for one-time corrections of severe monogenic diseases.
By Delivery Mechanism
Viral vectors held about 48% of delivery revenue in 2025. Lipid nanoparticles are the fastest-growing mechanism, with a 24.6% CAGR.
Regional Analysis
North America
North America is the largest region, with about 48% share in 2025, and is expected to reach about USD 8.76 billion by 2035.
.webp)
Europe
Europe is the second-largest market, supported by EU conditional authorization of Casgevy and strong academic CRISPR research.
Asia Pacific
Asia Pacific is the fastest-growing region, with a 17.3% CAGR and about 18% of global revenue in 2025, driven by trial activity in China and Japan's regulatory pathways.
LAMEA
LAMEA is projected to grow at a 13.2% CAGR, driven by hemoglobinopathy prevalence and Gulf healthcare investment.
Key Developments
- March 2025: Intellia reported positive Phase 3 interim data for an in vivo CRISPR-LNP therapy for hereditary angioedema, with a mean 95% reduction in attack rates at 6 months.
- January 2025: Beam Therapeutics signed a base editing licensing deal with Pfizer valued at up to USD 1.05 billion, including USD 300 million upfront.
Table of Contents
Explore the chapters covered in the full report.
Chapter 1. Report Introduction
- 1.1 Report Description
- 1.1.1 Purpose of the Report
- 1.1.2 USP & Key Offerings
- 1.2 Key Benefits For Stakeholders
- 1.3 Target Audience
- 1.4 Report Scope
Chapter 2. Market Overview
- 2.1 Market Definition & Scope
- 2.2 Key Market Takeaways
- 2.3 Market Snapshot
Chapter 3. Market Dynamics (DRO)
- 3.1 Drivers
- 3.2 Restraints
- 3.3 Opportunities
- 3.4 Market Trends
Chapter 4. CRISPR Gene Editing Therapies Market - Market Segmentation
- 4.1 Segment Overview
- 4.2 Market Size & Forecast by Segment
Chapter 5. CRISPR Gene Editing Therapies Market - Regional Analysis
- 5.1 North America
- 5.2 Europe
- 5.3 Asia Pacific
- 5.4 Middle East & Africa
- 5.5 Latin America
Chapter 6. Competitive Landscape
- 6.1 Market Share Analysis
- 6.2 Company Benchmarking
- 6.3 Strategic Developments
Chapter 7. Company Profiles
- 7.1 CRISPR Therapeutics AG
- 7.2 Vertex Pharmaceuticals Incorporated
- 7.3 Intellia Therapeutics Inc.
- 7.4 Editas Medicine Inc.
- 7.5 Beam Therapeutics Inc.
- 7.6 Prime Medicine Inc.
- 7.7 Caribou Biosciences Inc.
- 7.8 Allogene Therapeutics Inc.
- 7.9 Verve Therapeutics Inc.
- 7.10 Precision BioSciences Inc.
Chapter 8. Research Methodology
- 8.1 Research Approach
- 8.2 Data Collection & Sources
- 8.3 Market Estimation & Forecasting
- 8.4 Data Validation & Triangulation
Chapter 9. Standard Report Commercials & Add-Ons
Chapter 10. List Of Figures
Chapter 11. List Of Tables
Company Listing
- CRISPR Therapeutics AG
- Vertex Pharmaceuticals Incorporated
- Intellia Therapeutics Inc.
- Editas Medicine Inc.
- Beam Therapeutics Inc.
- Prime Medicine Inc.
- Caribou Biosciences Inc.
- Allogene Therapeutics Inc.
- Verve Therapeutics Inc.
- Precision BioSciences Inc.
Market Segments
Market Segmentation
Segmented by type (ex vivo, in vivo), technology (Cas9, Cas12, Cas13, base editing, prime editing, other), application (genetic disorders, oncology, infectious diseases, ophthalmology, cardiovascular, other), delivery mechanism (viral vectors, lipid nanoparticles, ribonucleoproteins, other), end use, and region.
Frequently asked questions
Which region grows fastest?
Which region dominates?
What is the projected market size?
How does pricing affect the market?
Who are the key players?
Need a tailored view of this market?
Ask our analysts to adapt the scope for your priority geographies, competitive set, customer segments, or strategic questions.
Request Customisation → Request a Sample